Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
GPR20 is a class-A orphan G protein-coupled receptor (GPCR) and a potential therapeutic target for gastrointestinal stromal tumors (GIST) owing to its differentially high expression. An antibody-drug conjugate (ADC) containing a GPR20-binding antibody (Ab046) was recently developed in clinical trials for GIST treatment. GPR20 constitutively activates Gi proteins in the absence of any known ligand, but it remains obscure how this high basal activity is achieved. Here we report three cryo-EM structures of human GPR20 complexes including Gi-coupled GPR20 in the absence or presence of the Fab fragment of Ab046 and Gi-free GPR20. Remarkably, the structures demonstrate a uniquely folded N-terminal helix capping onto the transmembrane domain and our mutagenesis study suggests a key role of this cap region in stimulating the basal activity of GPR20. We also uncover the molecular interactions between GPR20 and Ab046, which may enable the design of tool antibodies with enhanced affinity or new functionality for GPR20. Furthermore, we report the orthosteric pocket occupied by an unassigned density which might be essential for exploring opportunities for deorphanization.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9971246 | PMC |
| http://dx.doi.org/10.1038/s41421-023-00520-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Single-cell atlas efforts have reshaped the way we understand cells across the human body. Despite their power, they have not been effectively used to study ovarian biology in the context of other tissues, nor have they comprehensively incorporated healthy tissues from pre-menopausal donors. A focused pre-menopausal single-cell atlas could both advance our understanding of this life stage and support identification of ovarian gene targets for indications prevalent among younger demographics, such as fertility management.
View Article and Find Full Text PDFExploring the constitutive activation mechanism of the class A orphan GPR20.
Acta Pharmacol Sin
February 2025
Key Laboratory of Protection, Development and Utilization of Medicinal Resources in Liupanshan Area, Ministry of Education, Peptide & Protein Drug Research Center, School of Pharmacy, Ningxia Medical University, Yinchuan, 750004, China.
Article Synopsis
- GPR20 is an orphan G protein-coupled receptor that is highly expressed in intestinal tissue and may serve as a therapeutic target for gastrointestinal stromal tumors.
- This study investigates the mechanism of GPR20's constitutive activation using large-scale molecular dynamics simulations, revealing the involvement of allosteric signal transduction across different domains of the receptor.
- Findings indicate that both the N-terminal cap of GPR20 and G protein are essential for its active state, with the N-terminal cap acting like an agonist to enable conformational changes, thus advancing understanding for drug development targeting GPR20.
Upregulation of Siglec-6 induces mitochondrial dysfunction by promoting GPR20 expression in early-onset preeclampsia.
J Transl Med
July 2024
Clinical and Translational Research Center, Department of Obstetrics, Shanghai Key Laboratory of Maternal Fetal Medicine, Shanghai Institute of Maternal-Fetal Medicine and Gynecologic Oncology, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University, Shanghai, China. step
Article Synopsis
- Preeclampsia, particularly early-onset preeclampsia (EO-PE), is a serious pregnancy complication potentially linked to mitochondrial dysfunction, although the exact mechanisms are not fully understood.
- Researchers studied the role of Siglec-6 in placentas from healthy pregnancies and EO-PE cases, finding that Siglec-6 expression is elevated in EO-PE and that it negatively impacts trophoblast cell migration, invasion, and mitochondrial function.
- The pathway involving Siglec-6 and GPR20 is crucial for understanding trophoblast mitochondrial function, suggesting that these molecules could be valuable markers and therapeutic targets for EO-PE in clinical settings.
A Phase I, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients with Advanced Gastrointestinal Stromal Tumor.
Clin Cancer Res
September 2023
Department of General Internal Medicine/Developmental Therapeutics/Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Purpose: To evaluate DS-6157a, an antibody-drug conjugate targeting G protein-coupled receptor 20 (GPR20), in gastrointestinal stromal tumors (GIST).
Patients And Methods: In this phase I multicenter, open-label, multiple-dose study, patients with previously treated advanced GIST received intravenous DS-6157a on Day 1 of 21-day cycles, with a starting dose of 1.6 mg/kg.
Exploring genome-wide differentiation and signatures of selection in Italian and North American Holstein populations.
J Dairy Sci
August 2023
Department of Agricultural, Environmental and Food Sciences, University of Molise, Via A. De sanctis, 86100 Campobasso (CB), Italy.
Among Italian dairy cattle, the Holstein is the most reared breed for the production of Parmigiano Reggiano protected designation of origin cheese, which represents one of the most renowned products in the entire Italian dairy industry. In this work, we used a medium-density genome-wide data set consisting of 79,464 imputed SNPs to study the genetic structure of Italian Holstein breed, including the population reared in the area of Parmigiano Reggiano cheese production, and assessing its distinctiveness from the North American population. Multidimensional scaling and ADMIXTURE approaches were used to explore the genetic structure among populations.
View Article and Find Full Text PDF